RPM -- FDA is running late on product approvals, as it implements the many provisions in the FDA Amendments Act. But now the agency is saying that it will be late on FDAAA deadlines as well. Of the dozen or so provisions with approaching deadlines, the priority review voucher program is one of special interest to drug sponsors.